Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021, at 5:00 p.m. ET.
A live audio webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the fireside chat.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005337/en/